Format

Send to

Choose Destination
Womens Health (Lond). 2008 Mar;4(2):119-24. doi: 10.2217/17455057.4.2.119.

Insulin aspart in diabetic pregnancy: state of the art.

Author information

1
State University Hospital of Copenhagen, Centre for pregnant women with diabetes, Department of Endocrinology, Rigshospitalet, Blegdamsvej, DK 2100 Copenhagen, Denmark. em@rh.dk

Abstract

Pregnancy in women with diabetes is associated with an increased risk of obstetric complications and perinatal mortality. Maintenance of near-normal glycemia during pregnancy can bring the prevalence of fetal, neonatal and maternal complications closer to that of the nondiabetic population. Changes in insulin requirements during pregnancy necessitate short-acting insulins for postprandial control of hyperglycemia. The fast-acting insulin analogue insulin aspart has been tested in a large, randomized trial of pregnant women with Type 1 diabetes and offers benefits in control of postprandial hyperglycemia with a tendency towards fewer episodes of severe hypoglycemia compared with human insulin. Treatment with insulin aspart was associated with a tendency toward fewer fetal losses and preterm deliveries than treatment with human insulin. Insulin aspart could not be detected in the fetal circulation and no increase in insulin antibodies was found. Thus, the use of insulin aspart in pregnancy is regarded safe.

PMID:
19072511
DOI:
10.2217/17455057.4.2.119
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center